Key Points
- General Counsel Benjamin Landry sold 70,000 Health Catalyst shares at an average $1.43 each, worth $100,100, reducing his position by 19.92% to 281,372 shares. He also sold another 29,478 shares the following day at an average $1.39.
- Health Catalyst reported quarterly revenue of $56.28 million and a loss of $0.03 per share, beating analyst estimates of $55.39 million in revenue and a $0.05-per-share loss. Its net margin remained negative at 74.24%.
- Analyst sentiment was cautious: the stock had an average “Reduce” rating and a consensus price target of $2.01; shares were trading at $1.51 in the article.
Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 70,000 shares of the business's stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $1.43, for a total transaction of $100,100.00. Following the sale, the general counsel owned 281,372 shares in the company, valued at approximately $402,361.96. This trade represents a 19.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.
Benjamin Landry also recently made the following trade(s):
- On Thursday, November 12th, Benjamin Landry sold 29,478 shares of Health Catalyst stock. The stock was sold at an average price of $1.39, for a total transaction of $40,974.42.
Health Catalyst Stock Performance
Shares of Health Catalyst stock traded up $0.15 during trading on Friday, hitting $1.51. The company's stock had a trading volume of 465,291 shares, compared to its average volume of 348,183. The company has a fifty day simple moving average of $1.69 and a two-hundred day simple moving average of $1.68. The company has a market capitalization of $114.99 million, a PE ratio of -0.53 and a beta of 1.52. Health Catalyst, Inc. has a 52 week low of $0.96 and a 52 week high of $3.02.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. Health Catalyst had a negative net margin of 74.24% and a negative return on equity of 4.84%. The company had revenue of $56.28 million during the quarter, compared to analysts' expectations of $55.39 million. As a group, analysts predict that Health Catalyst, Inc. will post -0.18 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have weighed in on HCAT shares. Wells Fargo & Company decreased their target price on shares of Health Catalyst from $1.75 to $1.50 and set an "equal weight" rating for the company in a research note on Thursday, August 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Health Catalyst in a research report on Monday, October 26th. Citigroup dropped their price target on Health Catalyst from $2.50 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group downgraded Health Catalyst from a "buy" rating to a "hold" rating and cut their price target for the stock from $3.00 to $1.80 in a research note on Thursday, August 20th. Five analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Health Catalyst presently has an average rating of "Reduce" and a consensus target price of $2.01.
Check Out Our Latest Analysis on HCAT
Hedge Funds Weigh In On Health Catalyst
Hedge funds have recently bought and sold shares of the company. Palogic Value Management L.P. bought a new stake in Health Catalyst in the 2nd quarter worth about $9,796,000. BlackRock Inc. purchased a new position in Health Catalyst in the 2nd quarter worth about $3,654,000. Marshall Wace LLP purchased a new position in Health Catalyst in the 3rd quarter worth about $1,810,000. Hsbc Holdings PLC bought a new position in Health Catalyst during the 2nd quarter valued at about $809,000. Finally, Squarepoint Ops LLC lifted its stake in Health Catalyst by 1,214.8% during the 2nd quarter. Squarepoint Ops LLC now owns 400,210 shares of the company's stock valued at $796,000 after acquiring an additional 369,772 shares during the period. Institutional investors own 85.00% of the company's stock.
Health Catalyst Company Profile
(
Get Free Report)
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company's offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
